Lamivudine

Results: 316



#Item
1DEPARTMENT OF BIOCHEMISTRY FRONTIERS PROFESSOR KENNETH JOHNSON Roger J. Williams Centennial Professor of Biochemistry, University of Texas, USA DATE

DEPARTMENT OF BIOCHEMISTRY FRONTIERS PROFESSOR KENNETH JOHNSON Roger J. Williams Centennial Professor of Biochemistry, University of Texas, USA DATE

Add to Reading List

Source URL: bch.nus.edu.sg

Language: English - Date: 2015-08-20 23:15:40
2Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le

Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le

Add to Reading List

Source URL: www.anrs.fr

Language: French - Date: 2015-08-31 09:43:58
    3Microsoft WordNational Summit Evaluation

    Microsoft WordNational Summit Evaluation

    Add to Reading List

    Source URL: www.hivforum.org

    Language: English - Date: 2015-09-18 11:06:39
    4Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le

    Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le

    Add to Reading List

    Source URL: www.anrs.fr

    Language: French - Date: 2015-08-31 09:43:58
      5HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas

      HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas

      Add to Reading List

      Source URL: cdn.salix.com

      Language: English - Date: 2014-07-10 09:25:59
      6MULTI-­‐TARGET	
  PREDICTION	
   	
   Willem	
  Waegeman	
   NGDATA	
  Europe	
   Belgium	
  

      MULTI-­‐TARGET  PREDICTION     Willem  Waegeman   NGDATA  Europe   Belgium  

      Add to Reading List

      Source URL: www.ngdata.com

      Language: English - Date: 2014-03-18 20:25:45
      7HIGHLIGHTS OF PRESCRIBING INFORMATION   New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine

      HIGHLIGHTS OF PRESCRIBING INFORMATION  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine

      Add to Reading List

      Source URL: www.gilead.com

      Language: English - Date: 2013-10-28 13:55:09
      8Research Article Asian Journal of Pharmaceutical and Clinical Research LAMIVUDINE LOADED MICROSPHERES FOR ORAL USE: DESIGN, DEVELOPMENT AND ESTABLISHMENT OF INVIVO-INVITRO CORRELATION *1

      Research Article Asian Journal of Pharmaceutical and Clinical Research LAMIVUDINE LOADED MICROSPHERES FOR ORAL USE: DESIGN, DEVELOPMENT AND ESTABLISHMENT OF INVIVO-INVITRO CORRELATION *1

      Add to Reading List

      Source URL: www.ajpcr.com

      Language: English - Date: 2014-07-10 04:13:44
      9Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S

      Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S

      Add to Reading List

      Source URL: shionogi616.tew-staging.com

      Language: English - Date: 2014-11-03 11:26:22
      10   Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir  in Treatment‐Naïve Adults with HIV‐1    

        Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir  in Treatment‐Naïve Adults with HIV‐1    

      Add to Reading List

      Source URL: shionogi616.tew-staging.com

      Language: English - Date: 2014-11-03 11:26:21